(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2014 (25.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/149939 A1

(51) International Patent Classification:
A61K 47/10 (2006.01) *A61K 9/08* (2006.01)
A61K 47/26 (2006.01) *A61K 31/167* (2006.01)

(21) International Application Number:
PCT/US2014/021590

(22) International Filing Date:
7 March 2014 (07.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
765/DEL/2013 15 March 2013 (15.03.2013) IN

(71) Applicants: **NOVARTIS CONSUMER HEALTH INC.** [US/US]; 200 Kimball Drive, Parsippany, NJ 07054 (US). **NOVARTIS HEALTHCARE PRIVATE LIMITED** [IN/IN]; Sandoz House, Shrivsagar Estate Dr Annie Besant Road, Worli, Mumbai 400 018 (IN).

(72) Inventors: **BHARATI, Mahesh, Sudhakar**; Novartis Healthcare Private Limited, Sandoz House Shrivsagar Estate Dr Annie, Besant Road Worli, Mumbai 400 018 (IN). **YARABE, Houphouet, Hyacinthe**; Novartis Consumer Health Inc., 200 Kimball Drive, Parsippany, NJ 07054 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2014/149939 A1

(54) **Title**: DYE FREE LIQUID THERAPEUTIC SOLUTION

(57) **Abstract**: A liquid composition is provided. The composition includes at least one active pharmaceutical ingredient dissolved in a liquid carrier system. The liquid carrier includes polyethylene glycol and a co-solvent selected from the group consisting of: propylene glycol, glycerin, and a sugar alcohol. The composition is essentially dye free, present as a single-phase at room temperature, and optionally contains water.